Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

AstraZeneca's phase III zibotentan trial in CRPC does not meet primary endpoint

Sep. 28, 2010

MRC Technology patents novel protein kinase inhibitors

Sep. 28, 2010

CHMP recommends approval of Tasigna in E.U. as first-line therapy for Ph+ CML

Sep. 28, 2010

PLX-4032 shows promise to treat BRAF mutation-positive melanoma

Sep. 28, 2010

NexMed and Bio-Quant present preclinical data on PrevOnco

Sep. 28, 2010

FDA orphan drug status for darinaparsin in peripheral T-cell lymphoma

Sep. 27, 2010

S*BIO obtains funding to support clinical programs

Sep. 27, 2010

FDA and EMA to review vandetanib for advanced medullary thyroid cancer

Sep. 27, 2010

Pro-Pharmaceuticals and Numoda collaborate on phase III Davanat trial

Sep. 27, 2010

University of Kansas claims new HSP 90 inhibitors

Sep. 27, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...